Swiss National Bank Legend Biotech Corp Transaction History

Swiss National Bank

$146 Billion
Q4 2024

A detailed history of Swiss National Bank transactions in Legend Biotech Corp stock. As of the latest transaction made, Swiss National Bank holds 166,994 shares of LEGN stock, worth $5.78 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

166,994

Previous 165,194 1.09%

Holding current value

$5.78 Million

Previous $8.05 Million 32.5%

% of portfolio

0.0%

Previous 0.01%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 10, 2025	BUY	$32.49 - $50.28 $58,482 - $90,504	1,800 Added 1.09%	166,994 $5.43 Million
Q3 2024 Nov 07, 2024	BUY	$43.55 - $59.88 $226,459 - $311,376	5,200 Added 3.25%	165,194 $8.05 Million
Q1 2024 May 07, 2024	BUY	$55.06 - $69.99 $330,360 - $419,939	6,000 Added 3.9%	159,994 $8.97 Million
Q4 2023 Feb 06, 2024	BUY	$57.25 - $69.74 $824,400 - $1 Million	14,400 Added 10.32%	153,994 $9.27 Million
Q3 2023 Nov 08, 2023	BUY	$63.16 - $76.5 $88,424 - $107,100	1,400 Added 1.01%	139,594 $9.38 Million
Q2 2023 Aug 09, 2023	SELL	$46.28 - $75.01 $448,916 - $727,597	-9,700 Reduced 6.56%	138,194 $9.54 Million
Q1 2023 May 10, 2023	BUY	$43.42 - $57.37 $998,660 - $1.32 Million	23,000 Added 18.42%	147,894 $7.13 Million
Q3 2022 Nov 09, 2022	BUY	$38.15 - $57.1 $114,450 - $171,300	3,000 Added 2.46%	124,894 $5.1 Million
Q1 2022 May 09, 2022	BUY	$31.02 - $48.18 $2.49 Million - $3.87 Million	80,294 Added 193.01%	121,894 $4.43 Million
Q4 2021 Feb 08, 2022	BUY	$41.14 - $56.98 $1.71 Million - $2.37 Million	41,600 New	41,600 $1.94 Million

Others Institutions Holding LEGN

# of Institutions

227

Shares Held

76.3M

Call Options Held

199K

Put Options Held

342K

View Full List

About Legend Biotech Corp

Ticker LEGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 167,403,008
Market Cap $5.8B
Description
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multipl...

More about LEGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Swiss National Bank with notifications on news.

Account

Swiss National Bank Legend Biotech Corp Transaction History